Literature DB >> 21881869

Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphate.

Malgorzata Pietruska1, Jan Pietruski, Katalin Nagy, Michel Brecx, Nicole Birgit Arweiler, Anton Sculean.   

Abstract

The aim of this study was to evaluate the 4-year clinical outcomes following regenerative surgery in intrabony defects with either EMD + BCP or EMD. Twenty-four patients with advanced chronic periodontitis, displaying one-, two-, or three-walled intrabony defect with a probing depth of at least 6 mm, were randomly treated with either EMD + BCP (test) or EMD alone (control). The following clinical parameters were evaluated at baseline, at 1 year and at 4 years after regenerative surgery: plaque index, gingival index, bleeding on probing, probing depth, gingival recession, and clinical attachment level (CAL). The primary outcome variable was CAL. No differences in any of the investigated parameters were observed at baseline between the two groups. The test group demonstrated a mean CAL change from from 10.8 ± 1.6 mm to 7.4 ± 1.6 mm (p < 0.001) and to 7.6 ± 1.7 mm (p < 0.001) at 1 and 4 years, respectively. In the control group, mean CAL changed from 10.4 ± 1.3 at baseline to 6.9 ± 1.0 mm (p < 0.001) at 1 year and 7.2 ± 1.2 mm (p < 0.001) at 4 years. At 4 years, two defects in the test group and three defects in the control group have lost 1 mm of the CAL gained at 1 year. Compared to baseline, at 4 years, a CAL gain of ≥3 mm was measured in 67% of the defects (i.e., in 8 out of 12) in the test group and in 75% of the defects (i.e., in 9 out of 12) in the control group. There were no statistically significant differences in any of the investigated parameters at 1 and at 4 years between the two groups. Within their limits, the present results indicate that: (a) the clinical improvements obtained with both treatments can be maintained over a period of 4 years, and (b) in two- and three-walled intrabony defects, the addition of BCP did not additionally improve the outcomes obtained with EMD alone. In two- and three-walled intrabony defects, the combination of EMD + BCP did not show any advantage over the use of EMD alone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881869     DOI: 10.1007/s00784-011-0611-2

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  42 in total

1.  Treatment of intrabony defects with guided tissue regeneration and enamel-matrix-proteins. An experimental study in monkeys.

Authors:  A Sculean; N Donos; M Brecx; E Reich; T Karring
Journal:  J Clin Periodontol       Date:  2000-07       Impact factor: 8.728

2.  Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study.

Authors:  A Sculean; P Windisch; G C Chiantella; N Donos; M Brecx; E Reich
Journal:  J Clin Periodontol       Date:  2001-05       Impact factor: 8.728

3.  Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration.

Authors:  A Sculean; N Donos; P Windisch; M Brecx; I Gera; E Reich; T Karring
Journal:  J Periodontal Res       Date:  1999-08       Impact factor: 4.419

4.  Enamel matrix derivative alone or in combination with a bioactive glass in wide intrabony defects.

Authors:  Bahar Kuru; Selçuk Yilmaz; Kiliçaslan Argin; Ulkü Noyan
Journal:  Clin Oral Investig       Date:  2006-05-16       Impact factor: 3.573

5.  Effect of autogenous cortical bone particulate in conjunction with enamel matrix derivative in the treatment of periodontal intraosseous defects.

Authors:  Luigi Guida; Marco Annunziata; Salvatore Belardo; Roberto Farina; Alessandro Scabbia; Leonardo Trombelli
Journal:  J Periodontol       Date:  2007-02       Impact factor: 6.993

6.  Smear removal and collagen exposure after non-surgical root planing followed by etching with an EDTA gel preparation.

Authors:  J P Blomlöf; L B Blomlöf; S F Lindskog
Journal:  J Periodontol       Date:  1996-09       Impact factor: 6.993

7.  Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report.

Authors:  L Heijl
Journal:  J Clin Periodontol       Date:  1997-09       Impact factor: 8.728

8.  The Gingival Index, the Plaque Index and the Retention Index Systems.

Authors:  H Löe
Journal:  J Periodontol       Date:  1967 Nov-Dec       Impact factor: 6.993

9.  Clinical evaluation of a biphasic calcium composite grafting material in the treatment of human periodontal intrabony defects: a 12-month randomized controlled clinical trial.

Authors:  Jamal M Stein; Stefan Fickl; Sareh Said Yekta; Ulrich Hoischen; Christina Ocklenburg; Ralf Smeets
Journal:  J Periodontol       Date:  2009-11       Impact factor: 6.993

10.  Tissue response to biphasic calcium phosphate ceramic with different ratios of HA/beta TCP in periodontal osseous defects.

Authors:  E B Nery; R Z LeGeros; K L Lynch; K Lee
Journal:  J Periodontol       Date:  1992-09       Impact factor: 6.993

View more
  21 in total

1.  Gene array of primary human osteoblasts exposed to enamel matrix derivative in combination with a natural bone mineral.

Authors:  Richard J Miron; Dieter D Bosshardt; Yufeng Zhang; Daniel Buser; Anton Sculean
Journal:  Clin Oral Investig       Date:  2012-05-03       Impact factor: 3.573

2.  Effects of enamel matrix proteins in combination with a bovine-derived natural bone mineral for the repair of bone defects.

Authors:  Richard J Miron; Lingfei Wei; Dieter D Bosshardt; Daniel Buser; Anton Sculean; Yufeng Zhang
Journal:  Clin Oral Investig       Date:  2013-05-08       Impact factor: 3.573

3.  Bone grafting material in combination with Osteogain for bone repair: a rat histomorphometric study.

Authors:  Yufeng Zhang; Dai Jing; Daniel Buser; Anton Sculean; Fatiha Chandad; Richard J Miron
Journal:  Clin Oral Investig       Date:  2015-07-15       Impact factor: 3.573

Review 4.  Enamel matrix derivative and bone grafts for periodontal regeneration of intrabony defects. A systematic review and meta-analysis.

Authors:  M Matarasso; V Iorio-Siciliano; A Blasi; L Ramaglia; G E Salvi; A Sculean
Journal:  Clin Oral Investig       Date:  2015-05-27       Impact factor: 3.573

Review 5.  Effect and timing of non-surgical treatment prior to periodontal regeneration: a systematic review.

Authors:  Luigi Nibali; George Pelekos; Olanrewaju Onabolu; Nikos Donos
Journal:  Clin Oral Investig       Date:  2015-05-10       Impact factor: 3.573

6.  Three-year results following regenerative periodontal surgery of advanced intrabony defects with enamel matrix derivative alone or combined with a synthetic bone graft.

Authors:  Thomas Hoffmann; Elyan Al-Machot; Jörg Meyle; Pia-Merete Jervøe-Storm; Søren Jepsen
Journal:  Clin Oral Investig       Date:  2015-07-15       Impact factor: 3.573

Review 7.  Long-term periodontal tissue outcome in regenerated infrabony and furcation defects: a systematic review.

Authors:  Eduardo Aleixo Figueira; Angélica Oliveira de Assis; Sheyla Christinne Lira Montenegro; Diego Moura Soares; Anna Angélica Araújo Barros; Euler Maciel Dantas; Bruno César de Vasconcelos Gurgel
Journal:  Clin Oral Investig       Date:  2014-10-09       Impact factor: 3.573

8.  In vitro characterization of a synthetic calcium phosphate bone graft on periodontal ligament cell and osteoblast behavior and its combination with an enamel matrix derivative.

Authors:  Richard J Miron; Dieter D Bosshardt; Anja C Gemperli; Michel Dard; Daniel Buser; Reinhard Gruber; Anton Sculean
Journal:  Clin Oral Investig       Date:  2013-04-26       Impact factor: 3.573

9.  Gene array of PDL cells exposed to Osteogain in combination with a bone grafting material.

Authors:  Richard J Miron; Yuang Shuang; Anton Sculean; Daniel Buser; Fatiha Chandad; Yufeng Zhang
Journal:  Clin Oral Investig       Date:  2016-01-08       Impact factor: 3.573

Review 10.  Calcium orthophosphates in dentistry.

Authors:  Sergey V Dorozhkin
Journal:  J Mater Sci Mater Med       Date:  2013-03-07       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.